Citius Pharma FY26 Q3 net loss narrows to $8.9 million; revenue turns to $1.5 million
Reuters2026/08/14 20:31- Citius Pharmaceuticals posted revenue of USD 1.49 million for the quarter, versus no revenue a year earlier.
- Net loss applicable to common stockholders narrowed to USD 8.86 million, or USD 0.34 per share, from USD 8.79 million, or USD 0.80.
- Cash and cash equivalents rose to USD 17.01 million at June 30, 2026, from USD 4.25 million at Sept. 30, 2025.
- LYMPHIR became available at 44 institutions; institutional vial orders from wholesalers rose 31% as new ordering institutions increased 80%.
- Management said near-universal payer coverage has been secured, with no reimbursement denials or preauthorization barriers reported to date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
